A number of exciting, high value drug candidates are being developed from NovaBiotics' cysteamine platform as much needed therapeutic interventions in infectious and respiratory disease

Cysteamine’s unique multi-modal action provides manifold advantages in tackling conditions such as cystic fibrosis Lynovex (NM001), drug resistant bacterial infections Nylexa (NM002) and chronic respiratory disease Mufrosyn (NM003).

Cysteamine has the advantage of more than 25 years of clinical use history for unrelated (metabolic) disease. NovaBiotics has discovered a number of novel applications for this molecule which are protected by the Company’s intellectual property estate.